Merck faces a looming financial crisis as it nears the 2028 expiration of patent protections for Keytruda, which currently accounts for half of its revenue. While the company reports a 4.9% revenue increase this quarter, its reliance on Keytruda places it as the most exposed major player to upcoming patent cliffs, with industry-wide revenue losses expected to exceed $300 billion. This contrasts sharply with competitors like Eli Lilly, who are demonstrating strong growth despite the challenging landscape.
“Merck · is losing patent protections · Keytruda · beginning in 2028”
“Keytruda · accounts for · roughly half of Merck's revenue · true”
“Merck's management · contends · current pipeline could generate · more than $70 billion worth of annual revenue 10 years from now”
“IBM · has raised dividend · every year for the past 31 years · true”
“IBM · software accounts for · roughly 45% of its total revenue · true”
“The Motley Fool Stock Advisor analyst team · identified · the 10 best stocks for investors · true”
“Stock Advisor total average return · is · 968% · true”
“S&P 500 · is · 202% · true”
“Pfizer · will be reporting results · this Tuesday · before the bell”
“Pfizer · beat analysts' revenue expectations · last quarter · reporting revenues of $17.56 billion”
“Pfizer · recorded · revenues of $17.56 billion · down 1.2% year on year”
“Pfizer · expects revenues · to be flat year on year · improving from the 7.8% decrease it recorded in the same quarter last year”
